Zacks Investment Research on MSN
Corvus Pharmaceuticals stock rallies 209% in a month: Here's why
Shares of Corvus Pharmaceuticals CRVS have skyrocketed 208.8% in a month. The massive stock price rally was observed after ...
In January 2026, Corvus Pharmaceuticals reported past positive Phase 1 data from cohort 4 of its placebo-controlled trial of soquelitinib for moderate to severe atopic dermatitis, and moved ahead with ...
Cash constraints are forcing Corvus Pharmaceuticals to clip the wings of its lead candidate. Rather than advance on multiple fronts, the biotech is focusing on cancers including T-cell lymphoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results